Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1697-1702, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oberhardt, B. J.
Right arrow Articles by Pritchard, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oberhardt, B. J.
Right arrow Articles by Pritchard, C. G.
Related Collections
Right arrow Laboratory Management
Right arrow Oak Ridge Conference
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 1997;43:1697-1702.)
© 1997 American Association for Clinical Chemistry, Inc.

Oak Ridge Conference

Point-of-care fibrinolytic tests: the other side of blood coagulation

Bruce J. Oberhardt1,a, Patrick D. Mize2 and Cynthia G. Pritchard2

1 Sanguinex, P.O. Box 98385, Raleigh, NC 27624-8685.

2 Cardiovascular Diagnostics, Inc., 5301 Departure Dr., Raleigh, NC 27616.
a Author for correspondence. Fax 919-676-5436; e-mail bjo{at}ntwrks.com


Abstract

Point-of-care (POC) coagulation tests with paramagnetic iron oxide particles have provided alternatives to testing previously done only in the laboratory. With this technology, POC fibrinolytic tests have followed quietly the trail blazed by POC clotting tests and have found specific applications. These include rapid verification of in vivo thrombolytic drug action by in vitro testing with subsequent quantitative drug monitoring of the systemic lytic state, and also the determination of in vitro thrombolytic drug response before the drug is actually administered, to individualize therapy by selection of the most appropriate drug. Other applications include POC coagulation factor assays associated with fibrinolysis, and most recently the POC screening of patients with fibrinolytic defects. In this latter application, plasma from cardiac catheterization (n = 19) and venous thrombosis (n = 47) patient groups were tested. Controls consisted of two independent donor pools (n = 10, n = 21) as negatives and two plasma samples with known genetic defects in the fibrinogen molecule (A{alpha}554 Arg -> Cys) as positives.




The following articles in journals at HighWire Press have cited this article:


Home page
 CLIN APPL THROMB HEMOSTHome page
T. W. Stief and J. Fareed
Point of Care: Diagnostics in Hemostasisthe Wrong Direction?
Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 191 - 195.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.